Under the pharmacologic activation of the transcriptional factor NR2F1, a master regulator of tumor cell dormancy, cancer cells acquire a dormant phenotype associated with the inhibition of cell cycle progression and mTOR signaling [14]. This evidence concerns the gene NR2F1 and cancer.